Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial

ConclusionThe present study suggested that anti-EGFR MAbs may increase the risk of fatigue in cancer patients.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research